Elizabeth R Brown - JoVE Visualize

Showing results (51-60 of 143) with videos related to

Pageof 15

Sort By:

AIDS Care|May 15, 2010

Determinants of failure to access care in mothers referred to HIV treatment programs in Nairobi, KenyaPhelgona A Otieno, Pamela K Kohler, Rose K Bosire, et al.

Journal of Acquired Immune Deficiency Syndromes (1999)|August 27, 2005

Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012Susan H Eshleman, Laura A Guay, Jing Wang, et al.

American Journal of Epidemiology|October 22, 2015

Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV preventionPamela M Murnane, Elizabeth R Brown, Deborah Donnell, et al.

Circulation. Cardiovascular Imaging|January 19, 2021

Spatially Weighted Coronary Artery Calcium Score and Coronary Heart Disease Events in the Multi-Ethnic Study of AtherosclerosisSteven Shea, Ana Navas-Acien, Daichi Shimbo, et al.

AIDS and Behavior|November 12, 2014

Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 TrialAriane van der Straten, Ashley Mayo, Elizabeth R Brown, et al.

Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2004

Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012)Susan H Eshleman, Laura A Guay, Anthony Mwatha, et al.

The Journal of Infectious Diseases|July 1, 2015

Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE StudyJames Y Dai, Craig W Hendrix, Barbra A Richardson, et al.

Pharmaceutical Research|June 17, 2015

Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 PreventionCharlene S Dezzutti, Sarah Yandura, Lin Wang, et al.

The Journal of Infectious Diseases|March 26, 2009

Comparison of CD4 cell count, viral load, and other markers for the prediction of mortality among HIV-1-infected Kenyan pregnant womenElizabeth R Brown, Phelgona Otieno, Dorothy A Mbori-Ngacha, et al.

AIDS (London, England)|October 18, 2005

Timing of maternal and neonatal dosing of nevirapine and the risk of mother-to-child transmission of HIV-1: HIVNET 024Benjamin H Chi, Lei Wang, Jennifer S Read, et al.

Pageof 15

Showing results (51-60 of 143) with videos related to

Sort By:

Pageof 15

AIDS Care|May 15, 2010

Determinants of failure to access care in mothers referred to HIV treatment programs in Nairobi, KenyaPhelgona A Otieno, Pamela K Kohler, Rose K Bosire, et al.

Journal of Acquired Immune Deficiency Syndromes (1999)|August 27, 2005

Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012Susan H Eshleman, Laura A Guay, Jing Wang, et al.

American Journal of Epidemiology|October 22, 2015

Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV preventionPamela M Murnane, Elizabeth R Brown, Deborah Donnell, et al.

Circulation. Cardiovascular Imaging|January 19, 2021

Spatially Weighted Coronary Artery Calcium Score and Coronary Heart Disease Events in the Multi-Ethnic Study of AtherosclerosisSteven Shea, Ana Navas-Acien, Daichi Shimbo, et al.

AIDS and Behavior|November 12, 2014

Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 TrialAriane van der Straten, Ashley Mayo, Elizabeth R Brown, et al.

Journal of Acquired Immune Deficiency Syndromes (1999)|January 15, 2004

Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012)Susan H Eshleman, Laura A Guay, Anthony Mwatha, et al.

The Journal of Infectious Diseases|July 1, 2015

Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE StudyJames Y Dai, Craig W Hendrix, Barbra A Richardson, et al.

Pharmaceutical Research|June 17, 2015

Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 PreventionCharlene S Dezzutti, Sarah Yandura, Lin Wang, et al.

The Journal of Infectious Diseases|March 26, 2009

Comparison of CD4 cell count, viral load, and other markers for the prediction of mortality among HIV-1-infected Kenyan pregnant womenElizabeth R Brown, Phelgona Otieno, Dorothy A Mbori-Ngacha, et al.

AIDS (London, England)|October 18, 2005

Timing of maternal and neonatal dosing of nevirapine and the risk of mother-to-child transmission of HIV-1: HIVNET 024Benjamin H Chi, Lei Wang, Jennifer S Read, et al.

Pageof 15